Amodiaquine Plus Artesunate Versus Lapdap Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi
Information source: Centers for Disease Control and Prevention
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Malaria, Falciparum
Intervention: Amodiaquine plus artesunate (Drug); chlorproguanil-dapsone plus artesunate (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Centers for Disease Control and Prevention Official(s) and/or principal investigator(s): Rachel N Bronzan, MD, MPH, Principal Investigator, Affiliation: Centers for Disease Control and Prevention
Summary
Sulfadoxine-pyrimethamine is the current first-line therapy for uncomplicated malaria in
Malawi. Significant resistance of the P. falciparum malaria parasite to this drug has led to
an imminent need for the government of Malawi to identify a new first-line therapy for
uncomplicated malaria and to implement that new therapy as policy. This protocol is the
second of two protocols whose combined purpose is to provide efficacy and side effect data
on four antimalarial drug combinations that are candidates for the next first-line therapy
for uncomplicated malaria in Malawi. This protocol aims to assess the acceptability and
tolerability of amodiaquine in Malawi. It is a double-blind study comparing amodiaquine plus
artesunate (AQ-Art, one of the candidate combination therapies) to chlorproguanil/dapsone
plus artesunate (CD-Art, another of the candidate combination therapies) in persons 5 years
and older, to see if there is a higher incidence of abdominal pain and/or refusal to take
the therapy in the AQ-Art group. Amodiaquine was removed from the Malawian national drug
registry in 1995 because of a perceived association with abdominal pain. Although no studies
were conducted to substantiate this, consensus among clinicians was that patients were
refusing amodiaquine with increasing frequency, citing abdominal pain as the reason, so the
drug was removed from the registry. Results from this study, along with the efficacy data
from the sister protocol in children under five years of age, will help guide the National
Malaria Control Program of Malawi in selecting their next first-line antimalarial therapy.
Clinical Details
Official title: A Double-blind Randomised Trial to Assess the Tolerability of Amodiaquine Plus Artesunate (AQ-Art) Versus Chlorproguanil Plus Dapsone Plus Artesunate (CDA) in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Primary outcome: Incidence of abdominal pain on days 1, 2, and 3 in the two treatment groups
Secondary outcome: Rate of adequate clinical and parasitological response at 14 daysRate of adequate clinical and parasitological response at 28 days Mean percent change in blood haemoglobin concentration between day 0 and day 28 Incidence of adverse events other than abdominal pain during the period of observation Rate of Early Treatment Failure (per WHO definition) Rate of Late Clinical Failure (per WHO definition) Rate of Late Parasitological Failure (per WHO definition) Percent of patients with a decrease in haemoglobin concentration Percent of patients with a decrease in haemoglobin concentration of >= 2g/dl Prevalence of parasitemia on Day 2 Prevalence of parasitemia on Day 3 Gametocyte prevalence on Day 14 Gametocyte prevalence on day 28
Eligibility
Minimum age: 5 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age five years or older
- Axillary temperature >= 37. 5 degrees Celsius
- Monoinfection with P. falciparum
- Parasitemia between 2000 and 200000 parasites/microliter
- Hemoglobin concentration >= 7g/dl
- Consent by the patient of patient's adult guardian
- Residence in the locality and willingness to attend for scheduled visits
- Negative urine pregnancy test in women age twelve years and older
Exclusion Criteria:
- Signs of severe or complicated malaria
- altered consciousness
- convulsions
- prostration (inability to sit/stand/suck/drink)
- respiratory distress or breathlessness
- jaundice
- abnormal breathing
- hemoglobinuria
- circulatory collapse
- persistent vomiting (cannot keep down liquids)
- evidence of a diagnosis other than malaria on physical examination
- presence of mixed infection
- presence of severe malnutrition (as evidenced by symmetrical edema involving at least
the feet, light hair color, or cachexia)
- contraindications to the antimalarial drugs used, especially history of allergy
- history of receiving a drug with antimalarial activity in the week prior to
enrollment
Locations and Contacts
Kawale Health Center, Lilongwe, Lilongwe District, Malawi
Machinga District Hospital, Liwonde, Machinga District, Malawi
Matiki Health Center, Dwangwa, Nkhotakota District, Malawi
Additional Information
Starting date: April 2005
Last updated: September 26, 2012
|